{"organizations": [], "uuid": "a20844fda1ea0cae6312530cdf265d170e7e3d15", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-redhill-biopharma-plans-to-meet-wi/brief-redhill-biopharma-plans-to-meet-with-fda-in-q2-of-2018-to-discuss-design-for-one-two-pivotal-phase-iii-studies-with-bekinda-12-mg-idUSASC09V84", "country": "US", "domain_rank": 408, "title": "BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.042, "site_type": "news", "published": "2018-04-09T19:19:00.000+03:00", "replies_count": 0, "uuid": "a20844fda1ea0cae6312530cdf265d170e7e3d15"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-redhill-biopharma-plans-to-meet-wi/brief-redhill-biopharma-plans-to-meet-with-fda-in-q2-of-2018-to-discuss-design-for-one-two-pivotal-phase-iii-studies-with-bekinda-12-mg-idUSASC09V84", "ord_in_thread": 0, "title": "BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "redhill biopharma ltd", "sentiment": "negative"}, {"name": "bekinda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - Redhill Biopharma Ltd:\n* PROVIDES SEMI ANNUAL BUSINESS UPDATE * PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-09T19:19:00.000+03:00", "crawled": "2018-04-10T12:54:38.004+03:00", "highlightTitle": ""}